You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The companies have signed on to a new public-private initiative organized by Wisconsin's governor intended to increase the state's testing capacity.
The screening platform, which uses the Cas13 nuclease to target RNA instead of DNA, can be used to design guide RNAs for CRISPR research.
The activity of the ABE8e editor is increased 590-fold compared to the activity of the ABE7.10, and it can be paired with a variety of Cas9 or Cas12 homologs.
The clinics see patients whose overall health may benefit from learning about their genetic predisposition for certain medical conditions.
More than 339,000 people have now consented to be part of the program, and more than 265,000 participants have completed the full program protocol.
The company said its Liberty16 device is capable of detecting viral infection quickly, and can be deployed where other PCR instruments are too big to go.
The initiative is aiming to solve some of the existing problems in genomics research and build a resource that takes a step beyond gnomAD.
The company is in talks with potential partners in the US and China to validate the assay on clinical samples and deploy it at a large scale.
The company recently inked deals with Mammoth Biosciences and Rutgers University to license a protein discovery platform and gene editing technology.
The company announced during its Q4 earnings call that it had acquired Paradigm Diagnostics and Viomics to fill out its expertise in cancer diagnostics.
A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.
Undark looks into how coronavirus-related shutdowns are affecting field researchers.
In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.
Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.